Medulloblastoma, a tumor in the primary neuroectodermal of the cerebellum, typically originates from the vermis. This tumor is the third most common tumor of the central nervous system (CNS), after meningiomas and glioblastoma (
1). The most common position of this tumor is the posterior cranial fossa. This tumor contains about 21.8% all primary malignant tumors of the nervous system in Iran (
2). Medulloblastoma as a primary tumor of cerebellum includes about 20% of pediatric tumors and 1% of adult brain tumors (
2). Due to advances in surgery, chemotherapy and radiotherapy, the prognosis of medulloblastoma has dramatically changed in the last 20 years. The disease-free survival of patients is approximately 10 years in the absence of spinal metastases (
2). The most common sites of systemic metastasis are bone, peritoneum, liver and lung but the overall systemic metastasis rarely occurs in a small number of patients and it has rarely been reported medulloblastoma with metastases in the spinal cord (
2). In the recent years, the survival rate of children with medulloblastoma show better results. This improvement is due to factors such as early diagnosis, better surgical technique, radiotherapy technique of all CNS and using active agents in radiotherapy. At present, the medulloblastoma divided into two categories: average risk and high-risk. In average risk, non-metastatic patients (M0) have no remaining or less than a 1.5 centimeter after surgery. We report such a case that patient’s symptoms were resolved after treatment.